A paper authored by members of an American Society of Clinical Oncology Task Force illuminates the importance of enabling patients to receive trial-related testing and care near their homes, rather than requiring patients to travel long distances to reach major research institutions.
Positive high-level results from the POTOMAC phase III trial showed one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone.
